"Medical cannabis unveils a crucial lesson in the anatomy and physiology of phytocannabinoids: achieving substantial relief with minimal adverse effects, showcasing the essence of understanding the intricate interactions between these compounds and the human body."

- Dr. Newton

CBT

CPT FOR PTSD

CLINICAL ...

https://clinicaltrials.ucsd.edu/cannabis

https://jcannabisresearch.biomedcentral.com/

Therapeutic Effects of Cannabis and Cannabinoids

FDA OUTLINE

https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process

FUNDING...

https://today.wayne.edu/medicine/news/2022/08/04/state-awards-wsu-researchers-additional-125-million-to-study-risk-and-benefits-of-cannabis-in-veterans-behavioral-health-care-49016

PUBLICATION

PDF FILE FOR DOWNLOAD

https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Medical-Use-of-Cannabis-Report-2016-en.pdf

RESEARCH PROGRAMS...

https://www.pcom.edu/research/research-areas/medical-cannabis.html

Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis

Cannabis: a multifaceted plant with endless potentials

see figure 1

breast cancer and

medical cannabis

BREAST CANCER

Tomko AM, Whynot EG, O'Leary LF, Dupré DJ. Anti-cancer potential of cannabis terpenes in a Taxol-resistant model of breast cancer. Can J Physiol Pharmacol. 2022;100(8):806-817. doi:10.1139/cjpp-2021-0792
Almeida CF, Teixeira N, Correia-da-Silva G, Amaral C. Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype. Molecules. 2021;27(1):156. Published 2021 Dec 28. doi:10.3390/molecules27010156
Dobovišek L, Krstanović F, Borštnar S, Debeljak N. Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment. Cancers (Basel). 2020;12(3):525. Published 2020 Feb 25. doi:10.3390/cancers12030525
Kisková T, Mungenast F, Suváková M, Jäger W, Thalhammer T. Future Aspects for Cannabinoids in Breast Cancer Therapy. Int J Mol Sci. 2019;20(7):1673. Published 2019 Apr 3. doi:10.3390/ijms20071673
Hashemi F, Zarrabi A, Zabolian A, et al. Novel Strategy in Breast Cancer Therapy: Revealing The Bright Side of Ginsenosides. Curr Mol Pharmacol. 2021;14(6):1093-1111. doi:10.2174/1874467214666210120153348
Yin R, Li T, Tian JX, Xi P, Liu RH. Ursolic acid, a potential anticancer compound for breast cancer therapy. Crit Rev Food Sci Nutr. 2018;58(4):568-574. doi:10.1080/10408398.2016.1203755
Chebet JJ, Ehiri JE, McClelland DJ, Taren D, Hakim IA. Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis. BMC Cancer. 2021;21(1):902. Published 2021 Aug 6. doi:10.1186/s12885-021-08639-1
Kim JA, Jang JH, Lee SY. An Updated Comprehensive Review on Vitamin A and Carotenoids in Breast Cancer: Mechanisms, Genetics, Assessment, Current Evidence, and Future Clinical Implications. Nutrients. 2021;13(9):3162. Published 2021 Sep 10. doi:10.3390/nu13093162

GENERAL

ECS - Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 2000;141(1):118-126. doi:10.1210/endo.141.1.7239
ECS - Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzmán M, Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 1999;463(3):235-240. doi:10.1016/s0014-5793(99)01639-7
ECS - De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A. 1998;95(14):8375-8380. doi:10.1073/pnas.95.14.8375
GEN - Farzaei MH, Bahramsoltani R, Rahimi R. Phytochemicals as Adjunctive with Conventional Anticancer Therapies. Curr Pharm Des. 2016;22(27):4201-4218. doi:10.2174/1381612822666160601100823

FUTURE ... MORE KILLER Ts

Khan S, Suryavanshi M, Kaur J, Nayak D, Khurana A, Manchanda RK, Tandon C, Tandon S. Stem cell therapy: A paradigm shift in breast cancer treatment. World J Stem Cells. 2021 Jul 26;13(7):841-860. doi: 10.4252/wjsc.v13.i7.841. PMID: 34367480; PMCID: PMC8316873.

INFLAMMATORY BREAST CANCER

Sinclair S, Swain SM. Primary systemic chemotherapy for inflammatory breast cancer. Cancer. 2010;116(11 Suppl):2821-2828. doi:10.1002/cncr.25166

WEAN MULTIPLE DRUG CLASSES ... 1. OPOIDS, 2. BENZODIAZEPINES, 3. DEPRESSION MEDICATIONS, 4. SEDATIVES 5. NON-SEDATIVE HYPNOTICS

Marijuana Dispensary & Quality Cannabis Products - TrulieveTrulieve is a leading provider in medical and recreational cannabis and CBD products. Visit our website or one of our 180+ cannabis dispensaries

Dr. Terel S. Newton, a board-certified Anesthesiologist and Pain Management Specialist, serves as Medical Director at Trulieve in Florida and is a medical advisor for Trulieve Georgia. With expertise in integrating medical marijuana for diverse conditions, he prioritizes pain management and medical cannabis advocacy. Recognized for his community service, education, and outreach, Dr. Newton emphasizes purpose and progress over popularity. He collaborates with innovators and communities to address healthcare disparities, investing in underserved areas for significant societal impact and healthcare expansion. .

Disclaimer: Information provided is for reference only and does not imply affiliation or endorsement with the mentioned individuals, companies, and websites. Content accuracy, completeness, and timeliness are not guaranteed. Inclusion of information and websites does not constitute endorsement. Users should exercise caution when accessing external content. See your medical, legal, finance, tax, spiritual and other professionals for discussion, guidance, planning, recommendations and greater understanding of the risks, benefits, options and ability to apply any information to your situation.

anti-nausea

Protocol for Managing Chemotherapy-Induced Nausea with Cannabinoids

Objective: To provide a guideline for the use of cannabinoids, specifically THC and CBD, in managing nausea induced by chemotherapy treatments.

Background: THC (Tetrahydrocannabinol) and CBD (Cannabidiol) have been identified as beneficial in managing nausea. Both substances offer distinct mechanisms for nausea relief, which can be particularly useful for chemotherapy patients. This protocol integrates the findings from key studies, including those by Parker LA, Rock EM, Limebeer CL, and Sharkey KA, Darmani NA, Parker LA, to offer a comprehensive approach to managing chemotherapy-induced nausea.

Cannabinoid Dosing Guidelines:

Initial Dosing:
- THC: Start with a dose ranging from 2.5 mg to 10 mg.
- CBD: Initial dosing should be between 10 mg to 25 mg.
- Administer the first dose 1-3 hours before chemotherapy to maximize effectiveness.
1:1 Tincture Adjustment:
- Begin with a 2.5 mg dose of THC combined with 2.5 mg of CBD for the initial two days.
- Increase to 5 mg of THC and 5 mg of CBD for the following two days.
- Continue to increase by 2.5 mg increments until substantial nausea relief is achieved. If side effects are observed, revert to the last tolerated dose.
- Preference for tinctures high in d-limonene is noted, though not mandatory, due to the dual mechanisms of THC and CBD in nausea relief.

Dosing Considerations:

Individual tolerance and the severity of nausea should guide dosing adjustments.
Special consideration is required for patients with stage IV cancer or multiple co-morbidities, especially concerning THC tolerance. Adjust other therapies aggressively and engage in discussions with patients, caregivers, and nursing staff.

Additional Nausea Management Strategies:

Antiemetic Medications: Such as ondansetron.
Acupressure or Acupuncture: Non-pharmacological options for nausea relief.
Aromatherapy: Utilizing d-limonene/linalool for their anti-nausea effects.
Hydration: Encourage patients to stay hydrated.
Relaxation Techniques: Techniques like meditation and deep breathing exercises can be beneficial.
Cold Therapy: Applying cold to the back of the patient's head and neck may offer relief.

Monitoring and Follow-Up:

Regular follow-ups with the patient to monitor the efficacy and tolerability of the treatment.
Maintain open communication with the treating oncologist to adjust the treatment plan as necessary.
Be available as a resource for managing additional chemotherapy-induced symptoms, including pain, PTSD, and anxiety.

References:

Note: This protocol serves as a guideline. Individual patient needs may vary, and treatments should be adjusted accordingly. Always consult with a healthcare professional before initiating any new treatment.

v4.8

HIGH Potency Warning: RSO and other medicines are very potent and only a very small amount is often needed for medically sensitive patients.

Example: An RSO tincture bootle 20mg/ml. (2%), can be taken at 5 mg per dose under the tongue. Typically, it starts to take effect in about 20-30 minutes, when taken under the tongue or applied to the sides of the cheek. When swallowed, effects may take 1-2 hours.

SHAKE THE BOTTLE before opening, for a more uniform concentration.
JOURNAL - effects to review with your DOCTORS and NURSES. Write the medicine, day/time, dose and effects over time.

Start .25 ml per dose twice daily. [5mg per dose].
After 3 days (only if needed), increase to 0.50 ml twice daily. [10mg per dose].
After 3 days (only if needed), increase to a full dropper (1ml), [This 20mg per dose].
Stop increasing if relief is achieved or if side effects develop. Call your healthcare professional.

Medium Potency:

Example: A 1:1 THC:CBD tincture, 30mg/ml total concentration (15mg THC and 15mg CBD per ml), designed for oral use. Typically, it starts to take effect in about 20-30 minutes, when taken under the tongue or applied to the sides of the cheek. When swallowed, effects may take 1-2 hours.

SHAKE THE BOTTLE before opening, for a more uniform concentration.
JOURNAL - effects to review with your DOCTORS and NURSES. Write the medicine, day/time, dose and effects over time.

Start with 0.33 ml per dose (1/3 dropper), which provides ~ 5mg THC and ~ 5mg CBD, administered once in the morning and once at night.

NOTE: If the patient is VERY sensitive, divide the dose into 2 (two) parts - separate the two halves by 4 hours.

After 3 days (if additional relief is needed), increase to 0.4 ml per dose, offering 6mg THC and 6mg CBD, taken once in the morning and once in the evening.
After another 3 days (only if necessary), adjust to 0.6 ml per dose, delivering 9mg THC and 9mg CBD.
If sufficient relief is achieved at any stage, maintain that dosage. If adverse reactions occur, cease incrementing the dose and consult a healthcare professional.

Low Potency:

Example: A CBD oil tincture, 100mg/ml concentration, suitable for sublingual administration. Effective within approximately 20-30 minutes.

SHAKE THE BOTTLE before opening, for a more uniform concentration.
JOURNAL - effects to review with your DOCTORS and NURSES. Write the medicine, day/time, dose and effects over time.

Begin with 0.5 ml per dose, once in the morning and once in the evening [50 mg per dose].
After 3 days (only if necessary), increase to 1 ml per dose, to be taken once in the morning and once in the evening [100mg per dose].
After another 3 days (only if necessary), increase to 1.5 ml per dose, which equates to [150mg per dose].
Continue this regimen only until symptoms are managed or until adverse effects occur. Consult your healthcare provider for any concerns or questions.

Interested in community outreach, project development, or research collaboration?

general / opioid alternatives contact: DrTerelNewton@gmail.com

mmtc / trulieve director contact info: Terel.Newton@Trulieve.com

Page updated

Google Sites

Report abuse